Utilization of genomic signatures to identify phenotype-specific drugs

PLoS ONE

Volumn 4, Issue 8, 2009, Pages

  Mori, Seiichi ^a,b   Chang, Jeffrey T ^a   Andrechek, Eran R ^a   Potti, Anil ^a   Nevins, Joseph R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PEPLEOMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROGESTERONE RECEPTOR; RAS PROTEIN; SIMVASTATIN; TAMOXIFEN; DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL ASSAY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG RESPONSE; DRUG SELECTIVITY; DRUG SENSITIVITY; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PHENOTYPE; ANIMAL; GENOMICS; NUDE MOUSE; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; GENOMICS; HUMANS; MICE; MICE, NUDE; PHARMACEUTICAL PREPARATIONS; PHENOTYPE;

EID: 69949096746     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0006772     Document Type: Article

References (49)

1. Herbst RS, Bajorin DF, Bleiberg H, Blum D, Hao d, et al. (2006) Clinical Cancer Advances 2005; major research advances in cancer treatment, prevention, and screening - a report from the American Society of Clinical Oncology. J Clin Oncol 24: 190-205.
2. Hehlmann R, Hochhaus A, Baccarani M (2007) Chronic myeloid leukaemia. Lancet 370: 342-350.
3. Trusheim MR, Berndt ER, Douglas FL (2007) Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat Rev Drug Discov 6: 287-293.
4. Yaziji H, Goldstein LC, Barry TS, Werling R, Hwang H, et al. (2004) HER-2 testing in breast cancer using parallel tissue-based methods. Jama 291: 1972-1977.
5. Balis FM (2002) Evolution of anticancer drug discovery and the role of cell-based screening. J Natl Cancer Inst 94: 78-79.
6. Gibbs JB (2000) Mechanism-based target identification and drug discovery in cancer research. Science 287: 1969-1973.
7. Shoemaker RH (2006) The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 6: 813-823.
8. Zanders ED (2000) Gene expression analysis as an aid to the identification of drug targets. Pharmacogenomics 1: 375-384.
9. Nevins JR, Potti A (2007) Mining gene expression profiles: expression signatures as cancer phenotypes. Nat Rev Genet 8: 601-609.
10. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98: 10869-10874.
11. van'T Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536.
12. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, et al. (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403: 503-511.
13. Ramaswamy S, Ross KN, Lander ES, Golub TR (2003) A molecular signature of metastasis in primary solid tumors. Nature Genetics 33: 59-54.
14. Potti A, Lancaster JM, Dressman HK, Bild A, Riedel RF, et al. (2006) A genomic strategy to guide the use of chemotherapeutic drugs in solid tumors. Nature Medicine 12: 1294-1300.
15. Bild AH, Yao G, Chang JT, Wang Q, Potti A, et al. (2006) Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439: 353-357.
16. West M, Blanchette C, Dressman H, Huang E, Ishida S, et al. (2001) Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci USA 98: 11462-11467.
17. Bild A, Yao G, Chang JT, Wang Q, Potti A, et al. (2006) Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439: 353-357.
18. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, et al. (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10: 515-527.
19. Pawitan Y, Bjohle J, Amler L, Borg AL, Egyhazi S, et al. (2005) Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population based cohorts. Breast Cancer Res 7: R953-964.
20. Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, et al. (2005) Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 24: 4660-4671.
21. Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, et al. (2006) X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 9: 121-132.
22. Shankavaram UT, Reinhold WC, Nishizuka S, Major S, Morita D, et al. (2007) Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study. Mol Cancer Ther 6: 820-832.
23. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach tomultiple testing. J Royal Stat Soc 57: 289-300.
24. von Tresckow B, von Strandmann EP, Sasse S, Tawadros S, Engert A, et al. (2007) Simvastatin-dependent apoptosis in Hodgkin's lymphoma cells and growth impairment of human Hodgkin's tumors in vivo. Haematologica 92: 682-685.
25. Mitin N, Rossman KL, Der CJ (2005) Signaling interplay in Ras superfamily function. Curr Biol 15: R563-574.
26. Karnoub Ae, Weinberg RA (2008) Ras oncogenes: split personalities. Nat Rev Mol Cell Biol 9: 517-531.
27. Cully M, You H, Levine AJ, Mak TW (2006) Beyond PTEN mutations: the P13K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 6: 184-192.
28. Ikediobi ON, Davies H, Bignell G, Edkins S, Stevens C, et al. (2006) Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol Cancer Ther 5: 2606-2612.
29. Tanaka H, Nishida K, Sugita K, Yoshioka T (1999) Antitumor efficacy of hypothemycin, a new Ras-signaling inhibitor. Jpn J Cancer Res 90: 1139-1145.
30. Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, et al. (2006) BRAF mutation predicts sensitivity to MEK inhibition. Nature 439: 274-275.
31. Samuels Y, Diaz LA, Schmidt-Kittler O, Cummins JM, Delong L, et al. (2005) Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7: 561-573.
32. Tobert JA (1987) New developments in lipid-lowering therapy: the role of inhibitors of hydroxymethylglutaryl-coenzyme A reductase. Circulation 76: 534-538.
33. Takahashi K, Ekimoto H, Aoyagi S, Koyu A, Kuramochi H, et al. (1979) Biological studies on the degradation products of 3-[(S)-1′-phenylethylamino]- propylaminobleomycin: a novel analog (pepleomycin). J Antibiot (Tokyo) 32: 36-42.
34. Campbell MJ, Esserman LJ, Zhou YT, Shoemaker M, Lobo M, et al. (2006) Breast cancer growth prevention by statins. Cancer Res 66: 8707-8714.
35. Thompson EW, Paik S, Brunner N, Sommers CL, Zugmaier G, et al. (1992) Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J Cell Physiol 150: 534-544.
36. Ferrara N, Hillan KJ, Gerber HP, Novotny W (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3: 391-400.
37. Staunton JE, Slonim DK, Coller HA, Tamayo P, Angelo MJ, et al. (2001) Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci U S A 98: 10787-19792.
38. Takata R, Katagiri T, Kanehira M, Tsunoda T, Shuin T, et al. (2005) Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res 11: 2625-2636.
39. Hsu DS, Balakumaran BS, Acharya CR, Vlahovic V, Walters KS, et al. (2007) Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer. J Clin Oncol 25: 4350-4357.
40. Dressman HK, Berchuck A, Chan G, Zhai J, Bild A, et al. (2007) An integrated genomic-based approach to individualized treatment of patients with advanced stage ovarian cancer. J Clin Oncol 25: 517-525.
41. Nesbit CE, Tersak JM, Prochownik EV (1999) MYC oncogenes and human neoplastic disease. Oncogene 18: 3004-3016.
42. Prochownik EV (2004) c-Myc as a therapeutic target in cancer. Expert Rev Anticancer Ther 4: 289-302.
43. Weinstein JN, Myers TG, O'Connor PM, Friend SH, Fornace AJ Jr, et al. (1997) An information-intensive approach to the molecular pharmacology of cancer. Science 275: 343-349.
44. Wei G, Twomey D, Lamb J, Schlis K, Agarwal J, et al. (2006) Gene expression based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell 10: 331-342.
45. Stegmaier K, Wong JS, Ross KN, Chow KT, Peck D, et al. (2007) Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma. PLoS Med 4: e122.
46. Hieronymus H, Lamb J, Ross KN, Peng XP, Clement C, et al. (2006) Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell 10: 321-330.
47. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, et al. (2006) The Connectivity Map: using gene expression signatures to connect small molecules, genes, and disease. Science 313: 1929-1935.
48. Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM (2005) Statins and cancer prevention. Nat Rev Cancer 5: 930-942.
49. Kumar AS, Benz CC, Shim V, Minami CA, Moore DH, et al. (2008) Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin users. Cancer Epidemiol Biomarkers Prev 17: 1028-1033.